cisplatin + gemcitabine + icotinib

This is a combination regimen consisting of three drugs used in the treatment of non-small cell lung cancer (NSCLC), particularly for patients with stage IIB to IIIA adenocarcinoma. The regimen involves sequential administration of gemcitabine and cisplatin (chemotherapy agents) followed by oral icotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). The mechanism of action combines DNA damage induction and inhibition by platinum-based chemotherapy (cisplatin), nucleoside analog incorporation into DNA leading to chain termination and apoptosis (gemcitabine), and selective inhibition of EGFR signaling pathways that drive tumor cell proliferation (icotinib)[1][7][10]. This combination has been studied as an induction therapy prior to surgical resection in select NSCLC patients.

Other names

GC plus icotinibgemcitabine/cisplatin/icotinib